BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3089597)

  • 1. Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
    Foster BJ; Clagett-Carr K; Marsoni S; Simon R; Leyland-Jones B
    Cancer Treat Rep; 1986 Aug; 70(8):1003-14. PubMed ID: 3089597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?".
    Bruckner HW
    Cancer Treat Rep; 1987 Jun; 71(6):666-8. PubMed ID: 3107816
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
    Kardinal CG; Luce JK
    Cancer Treat Rep; 1977 Dec; 61(9):1691-3. PubMed ID: 413624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentamethylmelamine: review of an aqueous analog of hexamethylmelamine.
    Foster BJ; Clagett-Carr K; Hoth D; Leyland-Jones B
    Cancer Treat Rep; 1986 Mar; 70(3):383-9. PubMed ID: 3082512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.
    Bonomi PD; Mladineo J; Morrin B; Wilbanks G; Slayton RE
    Cancer Treat Rep; 1979 Jan; 63(1):137-8. PubMed ID: 105805
    [No Abstract]   [Full Text] [Related]  

  • 6. Hexamethylmelamine: a critical review of an active drug.
    Foster BJ; Harding BJ; Leyland-Jones B; Hoth D
    Cancer Treat Rev; 1986 Dec; 13(4):197-217. PubMed ID: 3102057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of pentamethylmelamine in patients with previously treated malignancies.
    Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH
    Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hexamethylmelamine chemotherapy for disseminated endometrial cancer.
    Seski JC; Edwards CL; Copeland LJ; Gershenson DM
    Obstet Gynecol; 1981 Sep; 58(3):361-3. PubMed ID: 6791063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination chemotherapy with hexamethylamine (Hexalen, Altretamine, Hexastat) and sarcolysine in advanced ovarian carcinoma].
    Gershanovich ML; Livshits ME; Antipenkova VI
    Vopr Onkol; 2000; 46(5):604-7. PubMed ID: 11202196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
    Markman M; Blessing JA; Moore D; Ball H; Lentz SS
    Gynecol Oncol; 1998 Jun; 69(3):226-9. PubMed ID: 9648592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexamethylmelamine and pentamethylmelamine: an update.
    Hahn DA
    Drug Intell Clin Pharm; 1983 Jun; 17(6):418-24. PubMed ID: 6407810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
    Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
    Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase I trial of pentamethylmelamine.
    Ajani JA; Cabanillas FF; Bodey GP
    Cancer Treat Rep; 1982 May; 66(5):1227-8. PubMed ID: 6805950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma.
    Moore DH; Valea F; Crumpler LS; Fowler WC
    Gynecol Oncol; 1993 Oct; 51(1):109-12. PubMed ID: 8244164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer.
    Levin L; Hryniuk W
    Semin Oncol; 1987 Dec; 14(4 Suppl 4):12-9. PubMed ID: 3120317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice.
    Broggini M; Rossi C; Colombo T; D'Incalci M
    Cancer Treat Rep; 1982 Jan; 66(1):127-33. PubMed ID: 6796267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hexamethylmelamine. An evaluation of its role in the therapy of cancer.
    Legha SS; Slavik M; Carter SK
    Cancer; 1976 Jul; 38(1):27-35. PubMed ID: 820422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of pentamethylmelamine: a clinical and pharmacologic study.
    Ihde DC; Dutcher JS; Young RC; Cordes RS; Barlock AL; Hubbard SM; Jones RB; Boyd MR
    Cancer Treat Rep; 1981; 65(9-10):755-62. PubMed ID: 6791819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.
    Stehman FB; Ehrlich CE; Callangan MF
    Gynecol Oncol; 1984 Feb; 17(2):189-95. PubMed ID: 6423460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altretamine.
    Hansen LA; Hughes TE
    DICP; 1991 Feb; 25(2):146-52. PubMed ID: 1905441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.